FA2H Antibody

What is FA2H and what is its biological function?

FA2H (Fatty acid 2-hydroxylase) is an enzyme required for alpha-hydroxylation of free fatty acids and the formation of alpha-hydroxylated sphingolipids . It plays a crucial role in lipid homeostasis and metabolism within the central nervous system. The enzyme is involved in signaling pathways that regulate cell cycle exit via effects on cyclin-dependent kinase inhibitor expression . Mutations in the FA2H gene have been implicated in a distinct subtype of neurodegeneration with brain iron accumulation (NBIA), termed fatty acid hydroxylase-associated neurodegeneration (FAHN) . The protein's function in lipid signaling transduction highlights its importance in maintaining normal neurological function.

What are the expected molecular weights for FA2H in Western blot experiments?

When detecting FA2H using Western blot analysis, researchers should be aware of potential discrepancies between calculated and observed molecular weights. The calculated molecular weight is approximately 42.8 kDa (42791 Da) , but observed molecular weights may vary. Different antibody suppliers report varied observed molecular weights:

• 111 kDa as reported by Boster Bio antibodies

• 38-43 kDa as observed with FineTest antibodies

This variation might be due to post-translational modifications, the presence of splice variants, or different detection methods. Researchers should validate their specific antibody with appropriate positive controls to establish the expected banding pattern in their experimental system.

Which species can be detected with commercially available FA2H antibodies?

FA2H antibodies are available for various species, with different cross-reactivity profiles depending on the manufacturer:

When selecting an antibody for your research, ensure it has been validated for your species of interest and intended application .

How do FA2H mutations contribute to neurodegeneration?

Mutations in FA2H have been identified as causative for a distinct form of neurodegeneration with brain iron accumulation (NBIA), specifically referred to as fatty acid hydroxylase-associated neurodegeneration (FAHN) . These mutations may impact neurological function through several mechanisms:

• Disrupted myelin structure: FA2H is crucial for the production of 2-hydroxylated sphingolipids, which are important components of myelin sheaths.

• Altered cell cycle regulation: FA2H-mediated signaling regulates cell cycle exit in neural cells. Mutations may lead to premature apoptosis of terminally differentiated cells like neurons through effects on cyclin-dependent kinase inhibitor expression .

• Abnormal ceramide metabolism: FA2H mutations newly implicate abnormalities in ceramide metabolism in the pathogenesis of NBIA .

Neuroimaging of patients with FA2H mutations reveals T2 hypointensity in the globus pallidus, confluent T2 white matter hyperintensities, and profound pontocerebellar atrophy . Phenotypically, affected individuals exhibit spastic quadriparesis, ataxia, and dystonia with onset in childhood and episodic neurological decline .

What are the optimal conditions for Western blot detection of FA2H?

For optimal Western blot detection of FA2H protein, consider the following recommended conditions:

• Antibody dilutions:

  • Boster Bio antibody (A05657-1): 1:500-2000 dilution

  • FineTest antibody (FNab02926): 1:500-1:2000 dilution

• Incubation conditions:

  • Primary antibody: 4°C overnight incubation is commonly used

  • Secondary antibody: For Boster Bio antibody validation, Goat Anti-rabbit IgG IRDye 800 was used at 1:5000 dilution

• Sample preparation:

  • FA2H has been successfully detected in mouse heart cells using this methodology

  • Given the protein's role in lipid metabolism, special attention should be paid to complete solubilization of membrane fractions

• Expected results:

  • Be prepared for variation in observed molecular weights (see question 1.2)

  • Include positive controls such as brain tissue or cell lines known to express FA2H

How does FA2H function differ between central nervous system and peripheral tissues?

Interestingly, patients with FA2H mutations that cause FAHN typically lack peripheral neuropathy, which contrasts with what is observed in other related neurological disorders such as NAD (Neurodegeneration associated with brain iron accumulation). This phenotypic difference may be related to the presence of a second fatty acid hydroxylase activity in peripheral tissue that is absent in the central nervous system .

This suggests that FA2H function has greater redundancy in peripheral tissues, whereas in the CNS, FA2H may be the primary or sole enzyme responsible for specific hydroxylation reactions. This functional difference has important implications for understanding disease pathology and for designing targeted therapeutic approaches.

What are the most suitable applications for FA2H antibodies?

FA2H antibodies have been validated for several applications with varying suitability:

When designing experiments, researchers should consider:

• The specific question being addressed (protein expression, localization, etc.)

• Sample type (cell lysate, tissue section, bodily fluid)

• Required sensitivity and specificity

• Available positive and negative controls

How should FA2H antibodies be stored and handled for optimal performance?

Proper storage and handling of FA2H antibodies is crucial for maintaining activity and specificity:

• Long-term storage:

  • Store at -20°C for up to one year

  • Antibodies are typically supplied in PBS containing 50% glycerol and preservatives like 0.02% sodium azide

• Short-term storage:

  • For frequent use, store at 4°C for up to one month

  • Avoid repeated freeze-thaw cycles that can degrade antibody quality

• Working solutions:

  • Prepare fresh dilutions for each experiment when possible

  • If recycling is necessary, high-titer antibodies may be stored at 4°C for approximately one week and reused about three times, though this is generally not recommended

• Safety considerations:

  • Note that many antibody preparations contain sodium azide, which is toxic and requires appropriate handling precautions

What controls should be included when using FA2H antibodies?

Rigorous experimental design for FA2H antibody applications should include appropriate controls:

• Positive controls:

  • Tissues or cells known to express FA2H (brain tissue is recommended)

  • Recombinant FA2H protein (if available)

  • Overexpression systems (transfected cells)

• Negative controls:

  • Primary antibody omission

  • Tissues or cells known not to express FA2H

  • FA2H knockout samples (if available)

  • Blocking peptide competition assays (blocking peptides for some FA2H antibodies can be purchased)

• Loading/normalization controls:

  • Housekeeping proteins (β-actin, GAPDH) for Western blot

  • Total protein staining methods for Western blot

  • Isotype control antibodies for IHC

• Validation controls:

  • Multiple antibodies targeting different epitopes of FA2H

  • Correlation of protein detection with mRNA expression data

How can researchers distinguish between normal and pathological FA2H expression?

Distinguishing normal from pathological FA2H expression requires careful experimental design and interpretation:

• Quantitative methods:

  • Western blot with densitometry analysis, normalized to appropriate loading controls

  • ELISA for precise quantification of FA2H protein levels

  • qPCR for mRNA expression levels (as a complementary approach)

• Comparative analysis:

  • Always include age-matched and condition-matched controls

  • Compare expression across multiple brain regions in neurological studies

  • Consider developmental changes in FA2H expression

• Pathological indicators:

  • Changes in FA2H molecular weight (potential post-translational modifications)

  • Altered subcellular localization

  • Correlation with biochemical markers of lipid metabolism

  • Relation to clinical parameters or disease progression

• Functional readouts:

  • Assessment of downstream sphingolipid profiles

  • Evaluation of myelin integrity in neurological tissues

  • Investigation of cell cycle regulation markers in relevant cell types

What are common issues in FA2H detection and how can they be resolved?

Researchers may encounter several challenges when detecting FA2H:

• Molecular weight discrepancies:

  • Issue: Observed molecular weight (38-43 kDa or 111 kDa) differs from calculated (42.8 kDa)

  • Solution: Validate with positive controls; consider post-translational modifications or splice variants

• Weak signal:

  • Issue: Insufficient sensitivity in detecting endogenous FA2H

  • Solutions:

    • Optimize antibody concentration

    • Extended exposure times for Western blot

    • Enhanced detection systems (e.g., HRP-conjugated polymers)

    • Enrichment of membrane fractions where FA2H is localized

• Non-specific banding:

  • Issue: Multiple bands of unexpected sizes

  • Solutions:

    • Increase blocking stringency

    • Optimize antibody dilution

    • Include blocking peptide controls

    • Use gradient gels for better resolution

• Tissue-specific detection challenges:

  • Issue: Variable expression across tissues or difficulty detecting in specific samples

  • Solutions:

    • Optimize extraction methods for lipid-rich tissues

    • Consider alternative fixation methods for IHC

    • Validate antibody in the specific tissue/cell type of interest

How does FA2H expression relate to sphingolipid metabolism in research contexts?

FA2H plays a critical role in sphingolipid metabolism by catalyzing the alpha-hydroxylation of free fatty acids, which are subsequently incorporated into sphingolipids . When investigating this relationship:

• Experimental approaches:

  • Correlate FA2H protein levels with sphingolipid profiles using lipidomics

  • Study the impact of FA2H knockdown/overexpression on sphingolipid composition

  • Investigate the relationship between FA2H mutations and altered sphingolipid metabolism in disease models

• Functional implications:

  • Alpha-hydroxylated sphingolipids contribute to membrane stability, particularly in myelin

  • Changes in FA2H activity may affect lipid raft composition and associated signaling pathways

  • FA2H dysfunction may lead to altered ceramide levels, potentially affecting apoptotic pathways

• Disease relevance:

  • In FAHN, abnormal ceramide metabolism contributes to neurodegeneration

  • FA2H mutations impact signaling pathways that regulate cell cycle exit, potentially leading to premature apoptosis in neurons

  • The stepwise neurological deterioration observed in patients with FA2H mutations may relate to cumulative defects in sphingolipid metabolism

How can FA2H antibodies contribute to neurodegeneration research?

FA2H antibodies represent valuable tools for investigating neurodegeneration mechanisms:

• Diagnostic applications:

  • Characterization of FA2H expression in various forms of NBIA

  • Development of biomarkers for FAHN and related disorders

  • Distinguishing FAHN from other forms of neurodegeneration (e.g., NAD)

• Pathophysiology studies:

  • Investigation of FA2H expression in animal models of neurodegeneration

  • Analysis of FA2H in post-mortem brain samples from patients with various neurodegenerative conditions

  • Correlation of FA2H levels with disease progression or severity

• Therapeutic development:

  • Screening compounds that modulate FA2H expression or activity

  • Monitoring treatment responses in preclinical models

  • Developing targeted approaches to compensate for FA2H dysfunction

What are emerging techniques for studying FA2H function beyond traditional antibody applications?

Beyond conventional antibody applications, researchers are exploring innovative approaches to study FA2H:

• Advanced imaging techniques:

  • Super-resolution microscopy for precise subcellular localization

  • Live-cell imaging with fluorescently tagged FA2H to track dynamics

  • Label-free imaging methods to study lipid metabolism in situ

• Genetic engineering approaches:

  • CRISPR/Cas9-mediated genome editing to create cellular or animal models

  • Conditional knockout systems to study tissue-specific FA2H functions

  • Introduction of patient-specific mutations to study pathogenic mechanisms

• Functional genomics and systems biology:

  • RNA-seq to identify transcriptional networks affected by FA2H alterations

  • Proteomics to identify FA2H interaction partners

  • Metabolomics to comprehensively profile lipid changes in FA2H-deficient models

• Computational modeling:

  • Structural analysis of FA2H and prediction of mutation effects

  • Simulation of lipid metabolism pathways in normal and disease states

  • Integration of multi-omics data to understand FA2H in broader cellular contexts